Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	31.90B +62.6%
Revenue (ttm)	5.37B -33.3%
Net Income	3.58B +283.7%
EPS	4.66 +285.0%
Shares Out	770.09M
PE Ratio	10.25
Forward PE	15.81
Dividend	1.28 (2.79%)
Ex-Dividend Date	Jul 4, 2025

Volume	13,637,590
Average Volume	4,924,579
Open	47.00
Previous Close	45.92
Day's Range	46.89 - 48.20
52-Week Range	28.53 - 50.97
Beta	0.78
RSI	62.54
Earnings Date	Mar 31, 2026

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.